Combined cannabinoid therapy via an oromucosal spray

Area of Science:

• Pharmacology
• Neuroscience
• Cannabinoid Research

Background:

• Cannabis sativa L. compounds (cannabinoids) show therapeutic potential for pain and spasticity.
• Patients use cannabis for debilitating symptoms despite legal and social challenges.
• Existing treatments may have limitations, necessitating alternative therapies.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Sativex, a novel oromucosal cannabinoid spray.
• To assess Sativex's potential in managing various pain conditions and multiple sclerosis symptoms.
• To determine if Sativex minimizes psychotropic side effects associated with cannabinoids.

Main Methods:

• Development of Sativex, a combined cannabinoid oromucosal pump spray containing THC and CBD.
• Administration and titration of Sativex in healthy volunteers and patient cohorts.
• Clinical assessment of Sativex efficacy in patients with intractable pain, rheumatoid arthritis, and multiple sclerosis.

Main Results:

• Sativex demonstrated good tolerability and successful self-administration and self-titration.
• Efficacy was observed in patients with chronic neuropathic pain, cancer pain, rheumatoid arthritis, and multiple sclerosis (spasticity, central pain, bladder issues).
• No significant intoxication-like symptoms, tolerance, or withdrawal syndromes were reported.

Conclusions:

• Sativex is a well-tolerated and effective treatment option for various pain conditions and multiple sclerosis symptoms.
• The oromucosal spray delivery of THC and CBD offers therapeutic benefits with minimized psychotropic effects.
• Further research supports the clinical utility of cannabinoid-based medicines in managing chronic conditions.